Teva and Roche partner to expand patient access to Treanda® on the Chinese market
Teva and Roche recently announced a cooperation agreement on innovation to further expand patient access to Treanda® in China. Treanda® is the trade name of bendamustine hydrochloride developed by Teva independently, and was approved in China in 2018. It is commercially available for the treatment of inert B-cell non-Hodgkin's lymphoma (NHL) with disease progression during/after treatment with rituximab or rituximab-containing regimens.
Theodor Wee, General Manager of Teva China, commented, "We are pleased to be able to leverage Roche's leading commercial presence to enable access to treatment to more Chinese lymphoma patients, reduce disease recurrence and therefore improve their life quality.
Many Chinese media outlets attended the official online contract signing ceremony on 18 April between Teva & Roche attended by Theodor Wee, Teva China GM, and Vivian Bian, CEO of Roche Pharma China. Among others, China Daily, the largest English-language daily in China, covered the agreement in an article
It took more than 5 months from the initial contact through the negotiation process until the signature of the contract and a lot of energy, working collaboratively as cross-functional One Teva to close this deal.
The cooperation between Roche and Teva will lay a solid foundation for the combination of Treanda® with Roche's own Gazyva® (generic name: Obinutuzumab) and Polivy® (generic name: Polatuzumab Vedotin), allowing a stronger synergy of drugs to improve survival benefits to Chinese lymphoma patients in the future. The five-year survival rate of lymphoma patients in China is 39 percent, compared with about 70 percent in developed countries.